Development-stage biopharmaceutical company Verastem, Inc. is at the forefront of cancer treatment drug development and commercialization. Among its promising products in development is VS-6766, a clamp focused on rapidly accelerated fibrosarcoma (RAF) and mitogen-activated protein kinase (MEK) blocker. The company is also actively engaged in developing RAMP 201 and RAMP 202, clinical trials exploring the efficacy and safety of avutometinib and defactinib in patients with recurrent low grade serous ovarian cancer and KRAS and BRAF mutant non-small cell lung cancer, respectively. Verastem, Inc. has also secured license agreements with Chugai Pharmaceutical Co., Ltd. and Pfizer Inc. for the development, commercialization, and manufacture of cancer-fighting products containing avutometinib and FAK inhibitors. Furthermore, the company has signed a clinical collaboration agreement with Amgen, Inc. to explore the combination of its avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM. Incorporated in 2010, Verastem, Inc. is based in Needham, Massachusetts.
Verastem Oncology's ticker is VSTM
The company's shares trade on the NASDAQ stock exchange
They are based in Needham, Massachusetts
There are 51-200 employees working at Verastem Oncology
It is http://www.verastem.com/
Verastem Oncology is in the Healthcare sector
Verastem Oncology is in the Biotechnology industry
The following five companies are Verastem Oncology's industry peers: